guideline (EAACI/GA 2 LEN/WAO/EDF urticaria guideline) recommends to use H1-antihistamines in licensed dose as first-line therapy and up to 4 times the licensed dose as second-line treatment in
CholU. 3 Unfortunately, in many patients, this treatment is not sufficient to achieve complete symptom control. 4 Accordingly, CholU patients are commonly regarded as difficult to treat (Cases or case series [5] [6] [7] , and new therapeutic options are needed.
One prerequisite for the development of new treatment options is the availability of valid and reliable outcome measures to assess treatment effects. However, as of recently, such tools for CholU were largely missing. This might be one of the reasons why only very few randomized controlled clinical trials have been performed in CholU. Very recently, pulse-controlled ergometry provocation testing was introduced as an objective method for the diagnosis of CholU, 8 and the CholU activity score (CholUAS) was described as the first disease-specific diary-type tool to assess disease activity. 4 In addition to disease activity, health-related quality of life (QoL) is another important and recommended outcome measure in both routine patient care and clinical trials. Disease-specific QoL instruments such as the chronic urticaria quality-of-life questionnaire (CU-Q2oL)
and the angioedema quality-of-life questionnaire (AE-QoL) have been available for chronic spontaneous urticaria for years. [9] [10] [11] In contrast, specific tools for chronic inducible urticaria forms, including
CholU, are still missing, although leading health authorities strongly recommend the use of patient-reported outcome tools in randomized controlled trials. 12,13 Accordingly, we here report the development and validation of the first disease-specific health-related QoL instrument for CholU, the Cholinergic Urticaria Quality-of-Life Questionnaire (CholU-QoL). The development of the CholU-QoL was performed in 3 steps: (i) item generation, (ii) item selection and (iii) CholU-QoL validation.
| MATERIALS AND METHODS

| Item generation
Item generation was performed in accordance with current recommendations for patient-reported outcome instrument development. [12] [13] [14] [15] In brief, a CholU core development group (S.A., J.R., K.W.)
identified specific fields of disease-related QoL impairment that should be covered by the CholU-QoL. This group also defined the scoring system for CholU symptoms, anchors for the evaluation of the CholU-QoL performance and helped to design and conduct the item selection phase and the CholU-QoL validation study.
Item generation was performed using 3 concomitant and sequential strategies: (i) a literature search for published data on QoL impairment in CholU patients; (ii) semistructured interviews with 10 patients with a history of CholU who were recruited at the Department of Dermatology and Allergy, Charit e-Universit€ atsmedizin, Berlin and iii)
inclusion of CholU expert opinion of the core development group.
Item responses were designed as 5-point Likert scales (LS) 16 with the answer options "not at all"; "somewhat"; "moderately"; "much";
"very much" as well as "never," "seldom," "occasionally," "often" and "very often." The recall period of all items was chosen to be 7 days.
| Item selection
All questions identified in the item generation phase were administered to 50 CholU patients recruited at the Department of Dermatology and Allergy, Charit e-Universit€ atsmedizin, Berlin (36 females; mean age AE SD: 40.7 AE 15.6 years; median: 35; range 20-79).
These patients were asked to complete all items and to score their relevance and importance (impact analysis, see below). Furthermore, all patients were requested to rate the understandability and comprehensibility of the generated items. Item selection was subsequently performed by means of impact analysis, complemented by the core development group of the selection for face validity.
| Impact analysis
An impact analysis was performed to exclude all items from the final CholU-QoL with a low impact. To this end, patients were asked to rate each question regarding their importance (1 = not important to 5 = extremely important) and whether they had experienced the item content within the last year (yes/no). The "importance" and "frequency" of each item was then computed as the mean of all importance values and the proportion of patients who experienced the item content. Subsequently, the "impact score" was calculated for each item by multiplication of "frequency" and "importance." An impact score of >2.5 points was chosen as a cut-off point for the inclusion of items.
| Expert review
The impact analysis was complemented by a review of the core development group. Redundant and unprecise questions were eliminated, and a final assessment of the selected items for their face validity was performed. In addition, the recall period of the final CholU-QoL was changed from 7 to 14 days. This was based on patient input in the item selection phase and agreed on by the core development group. Each CholU-QoL item was scored from 0 to 4 points (0 = "not at all"/"no treatment"; 1 = "somewhat"; 2 = "moderately"; 3 = "much"; 4 = "very much"). The raw total score and the raw domain scores were calculated by adding up all respective item scores. Subsequently, all raw scores were linearly transformed to a 0-100 scale with higher scores indicating higher QoL impairment. The total score was not computed when >20% of the items (>5 items) were missing.
| CholU-QoL validation
The domain scores "symptoms," "functional life," "social interaction"
and "emotions" were not computed when more than 25% of the items were missing in the respective domain. The domain score "therapy" was not computed when >50% of the items were missing.
A total of 21 items throughout all analysed 88 questionnaires were missing (percentage of missing items = 0.85%).
For the CholU-QoL total score, it was expected that patients with a higher CholU-QoL score also score higher in the PGA-QoL (correlation coefficient r of at least .5).
| Convergent validity
The CholU-QoL total and domain scores were correlated for convergent validity with the following anchors:
1. PGA-disease activity-VAS and -LS: The patients' global assessment of disease activity visual analogue scale (PGA-disease activity-VAS) assesses urticaria activity during the previous 2 weeks on a 10-cm unmarked line anchored at the 2 ends with "no complaints" (0 cm) and "maximal complaints" (10 cm).
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The patients' global assessment of disease activity on a 4-point Likert scale (PGA-disease activity-LS) also assesses disease activity during the previous 2 weeks with the options "no complaints," "mild complaints," "moderate complaints" and "severe complaints." with the options "no impairment," "mild impairment," "moderate impairment" and "severe impairment." 16 
DLQI:
The DLQI questionnaire 17 measures skin health-related QoL, has a recall period of 7 days, consists of 10 questions, 6
subheadings ("symptoms and feelings," "daily activities," "leisure,"
"work and school," "personal relationships" and "treatment") and has a score that ranges from 0 to 30, with 0-1 points indicating no effect at all on the patient's life, 2-5 points: small effect on patient's life, 6-10 points: moderate effect on patient's life, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] points: very large effect on patient's life, and >20 points: extremely large effect on patient's life.
To assess the convergent validity of the CholU-QoL, the total and the domain scores were correlated (Spearman 
| Known-groups validity
Patients with different levels of disease activity (PGA-disease activity-LS) and QoL impairment (PGA-QoL-LS) and also different levels of disease control (UCT) were compared regarding their CholU-QoL total scores.
| Test-retest reliability
Thirty-seven CholU patients, whose therapy did not change, completed all items twice in a mean interval of 12 weeks (mean AE SD:
12.5 AE 9.6 weeks; median 10; range . To determine the testretest reliability of the CholU-QoL, we compared the CholU-QoL scores of (i) all 37 patients whose therapy did not change and (ii) 23 patients whose therapy did not change and whose PGA-disease activity-LS rating did not change from the first to the second assessment. The mean values of the 2 assessments were compared, and the intraclass correlation coefficient (ICC) was calculated. An ICC of .5-.7 represents moderate to good reproducibility, an ICC > .7 excellent reproducibility. 19, 24, 25 As model for ICC computation, 2-way mixed effects model and absolute agreement were chosen.
For health-related QoL instruments, at least moderate test-retest reliability is requested. Higher ICC values were expected in the subgroup of 23 patients with stable disease.
| Multiple linear regression analysis
Age (in years), gender and duration of disease (in years) were included in the multiple regression analysis (as independent variables) to detect drivers of the CholU-QoL total score (set as dependent variable). 3 | RESULTS
| CholU-QoL item generation and selection
The item generation phase resulted in 96 items possibly relevant for CholU patients. In the subsequent item selection phase, a total of 50 CholU patients took part. All of them (100%) stated no problems with understanding the items, 30 patients (60%) found it comprehensive and 20 patients (40%) gave comments about missing or improvable items that were reviewed by the core development group and frequent comments, for example regarding assessment duration, were respected in the item selection phase.
The impact analysis (see Table 1 ) revealed 37 items with an impact score >2.5 points. During the expert review for face validity, 10 of these 37 items (p6, p41, p42, p44, p48, p55, p56, p57, p61, p91) were excluded due to redundancy. In addition, items p3, p24, p40 and p81 were eliminated because of perceived impreciseness.
On the other hand, items p64 "burden due to treatment?," p66 "worried about drug side-effects," p67 "drug side-effects," p69 "frustrated" and p73 "depressed" slightly failed the >2.5 point cut-off, but were regarded as important by the core development group and included in the final CholU-QoL item set. The wording of item p12
was slightly modified to make it more precise. Finally, 28 items were selected for the final CholU-QoL questionnaire.
| CholU-QoL validation and first results
In the validation study, a total of 88 CholU patients were included (patient characteristics see Table 2 ). The explorative factor analysis revealed a 5-domain structure of the CholU-QoL ( Table 3 ) that explained 76.3% of its variance. According to the content of the assigned items, the 5 domains were termed "symptoms," "functional life," "social interaction," "therapy" and "emotions." Items were assorted to the domain with the highest factor loading. All but one item (sweat) could be accordingly assigned to one of the domains.
The item "sweat" was sorted to the domain "functional life" by the core development group for reasons of face validity, although its factor loading was highest for the domain "emotions." In the last step, the items were rearranged according to the CholU-QoL domain structure. The German and US American-Canadian English versions of the CholU-QoL are available as Supporting Information (see Appendices S1 and S2).
| Internal consistency reliability
Each CholU-QoL domain was tested for its internal consistency by computing the Cronbach 0 s a coefficient ( Table 4 ). The Cronbach 0 s a coefficient was >.9 for the domains "functional life," "social interaction" and "emotions," indicating excessive consistency and >.8 for the domains "symptoms" and "therapy," indicating excellent internal consistency. In addition, the Cronbach 0 s a coefficient for the CholUQoL total score was found to be .97, indicating that it is appropriate to compute a total score in addition to the 5 domain scores.
| CholU-QoL results
The results of the CholU-QoL total and the domain scores of the validation study are shown in Figure 1 . The distribution of the total and the domain scores was overall broad. Three patients (3.4%) scored the lowest possible total score of 0. No patient scored the highest possible total score of 100 points. The highest total score that was reached was 91 points.
| Convergent validity
The convergent validity was tested by correlating the CholU-QoL total and domain scores with the results of the anchor instruments (see Table 5 ). All correlations were significant and in the expected directions. The correlation coefficient was high (r > .8) for the correlations of the total scores, except for the correlation of the CholU-QoL scores with the CholUAS7 (r > .45). The highest correlation was seen between the CholU-QoL total score and the DLQI score (r = .88).
| Known-groups validity
Patients with different levels of disease activity (PGA-disease activity-LS) and QoL impairment (PGA-QoL-LS) had significant differences in CholU-QoL total scores (see Table 6 ). As expected, the CholUQoL total score increased with increasing levels of disease activity and health-related QoL impairment. The interquartile range of the CholU-QoL total scores of the different levels of disease activity and the health-related QoL impairment did not overlap, except for a small overlap of .5 points in the disease activity categories "mild"
and "moderate."
Furthermore, patients with uncontrolled symptoms (UCT < 11) scored higher in the CholU-QoL as compared to patients with controlled disease (UCT > 12). Again, the interquartile ranges did not overlap.
| Test-Retest reliability
When we analysed the scores of 37 patients, who completed the CholU-QoL twice, for test-retest reliability, CholU-QoL total and domain scores were not significantly different between the 2 timepoints (see Table 7 ). The ICC was .85 for the total score and between .76 and .86 for the domains "symptoms," "functional life"
and "social interaction" indicating excellent reproducibility (>.75). The ICC was lower for the domains "therapy" and "emotions" (.66 and .67), but still indicated moderate reproducibility. The ICC of the 23 patients with both criterions for disease stability fulfilled was .94 for the CholU-QoL total score and >.80 for all domains, except the domain "therapy" (.67) (see Table 8 ).
| Influence factors of the CholU-QoL total score
The multiple linear regression analysis did not reveal a significant influence of age, gender or duration of disease on the CholU-QoL total score (see Table 9 ).
T A B L E 3 Factor analysis
Items
Factor 1 (symptoms) Items with a factor loading >0.5 are printed in boldface.
RUFT ET AL. When looking at single CholU-QoL domains, we found that the domain "emotions" was most affected. However, the differences between the mean scores of the domains were rather small (between 39 and 44 points), except for the domain "therapy" with a mean score of 20 points. The small differences indicate an overall comparable impact of CholU on the different aspects of diseaserelated QoL represented by the 5 domains. The exception of the domain "therapy" may be explained by the way of computation of this domain score. "No treatment" was scored in the same way as the option "not at all" with 0 points. This computing was suggested by the core development group, as it was supposed that a patient who had a treatment that provokes additional side-effects has a stronger QoL impairment compared to a patient with no treatment.
When computing the domain score "therapy" only for the 60 patients who had treatment, the resulting mean domain score was 30 .0 (see Figure 1) , which is within the range of the results of the remaining subdomains.
The levels of convergent validity of the CholU-QoL total and domain scores with all anchor scores exceeded our expectations, except for the domain "therapy," most likely because not all patients had treatment and not all anchor instruments included questions on therapy. As anticipated, we determined that the correlation of the CholU-QoL with the QoL anchor, DLQI, was higher than the correlation with the anchors of disease activity (eg, CholUAS7). The reason is that the DLQI is conceptually closer to the CholU-QoL than the disease activity measures, and it is well known that disease activity usually only moderately correlates with QoL impairment. 28 The correlation of the UCT score and the CholU-QoL total score was also high and statistically significant, which shows a significant relation between the different levels of disease control and the impairment of QoL.
In the known-groups validity assessment of the CholU-QoL, the total score was different in patients with different levels of disease activity, globally rated QoL impairment and different levels of disease control. The very good results of the known-groups validity indicate the high discriminative ability of the CholU-QoL. Interestingly, this analysis clearly depicted the broad variation in QoL impairment in CholU patients, where many patients (58%) had no or mild interference in their life, but also 15% of the CholU patients had maximum QoL impairment (see Table 6 ). Furthermore, the UCT analysis showed that in 67%, the disease could not be controlled by the current therapy of the patients.
In the test-retest reliability analysis of the CholU-QoL, the ICC was excellent in stable patients, except for moderate to good reproducibility for the domains "therapy" and "emotions." The lower ICC for these domains may be due to the fact that the items of these domains assess the personal feelings of patients or their attitude towards the therapy (eg, anxiety, capacity to suffer), which can vary substantially. Another factor could be that the interval between the first and the second assessments was quite long in some patients, up to 29 weeks, and varied considerably.
Interestingly, the multiple linear regression analysis identified no significant influence factor on the CholU-QoL total score. This result is in contrast to similar QoL instruments, in which an influence of duration of disease 29 or of gender 22 was seen. These results showed that in CholU women and men, young and old suffer to same extent, and it does not matter how long the CholU persists.
The CholU-QoL is a 28-item questionnaire, which is easy and fast to complete for patients. In our experience, it takes patients <5 minutes to complete the CholU-QoL and it only takes another minute to calculate the total and domains scores. Twenty-eight is a fair number of items for a QoL instrument and comparable with The strengths of this work include that we investigated patients with a broad range of disease durations, disease activity and of different age classes, recruited independently at 2 centres, and that the CholU-QoL was correlated with many different validated QoL anchors, but also with specific disease activity (CholUAS7) and disease control (UCT) scores.
Limitations of this work include (i) that the development of the CholU-QoL did not include children with CholU and that we do not know yet how the CholU-QoL performs in older children and adolescents, (ii) that the sensitivity to change and the minimal important difference in the CholU-QoL have not been studied. The latter has to be performed in future studies to find out which score changes in the CholU-QoL overtime can be considered a meaningful change to the patient. 11 (iii) The sample size in our study was limited to 88 patients, as it was difficult to find more patients with confirmed diagnostic criteria of CholU, who were willing to participate in our study within a reasonable time frame.
Despite this limitation computations showed good results, and most likely would not give different results in a higher number of patients. (iv) Some of the patients included in this study had concomitant diseases including other forms of chronic urticaria. We decided to include these patients, because the coexistence of other conditions, for example a combination of different forms of chronic urticaria in the same patient is a common feature of all types of chronic urticaria including cholinergic urticaria. 30, 31 Of note, all patients in this study had confirmed diagnostic criteria of CholU and CholU, in patients with more than one type of chronic urticaria, was the dominant urticaria type."
As of yet, a German and an US American-Canadian English version of the CholU-QoL is available. To make this tool broadly available for future multinational trials, a linguistic validation for additional languages is desirable, similar to the approach used for other patient-reported outcomes in urticaria and angioedema. 20, 32 Future studies that use the CholU-QoL should look at the influence of treatment on QoL impairment 6, 33, 34 and the link of QoL impairment and psychological resources in CholU patients. 35 In conclusion, the CholU-QoL is the first instrument with excellent validity and reliability for the assessment of disease-specific 
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